Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1731-1738

  McCabe, Craig F ^a   McCabe, Shannon E ^a  

^a McCabe Vision Center   (United States)

Author keywords

Allergic conjunctivitis; Bepotastine besilate; Olopatadine hydrochloride; Patient preference

Indexed keywords

BEPOTASTINE; OLOPATADINE;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EYE DISCOMFORT; FEMALE; HUMAN; MALE; OCULAR PRURITUS; PATIENT ASSESSMENT; PATIENT COMFORT; PATIENT PREFERENCE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; TASTE DISORDER; TREATMENT OUTCOME;

EID: 84869229410     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S35431     Document Type: Article

References (21)

1. Manners T. Managing eye conditions in general practice. BMJ. 1997; 315:816-817.
2. Abelson MB, Loeffler O. Conjunctival allergen challenge: models in the investigation of ocular allergy. Curr Allergy Asthma Rep. 2003;3: 363-368.
3. Bielory L. Ocular allergy overview. Immunol Allergy Clin North Am. 2008;28:1-23.
4. Wüthrich B, Brignoli R, Canevascini M, Gerber M. Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweiz Med Wochenschr. 1998;128: 139-143. German.
5. Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, Bron AJ. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol. 2004;11:17-33.
6. Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc. 2007;28:393-397.
7. Niederkorn JY. Immune regulatory mechanisms in allergic conjunctivitis: insights from mouse models. Curr Opin Allergy Clin Immunol. 2008;8:472-476.
8. Leibowitz HM. The red eye. N Engl J Med. 2000;343:345-351.
9. Bepreve®. [Package insert]. Irvine, CA: ISTA Pharmaceuticals Inc; 2009.
10. Abelson MB, Torkildsen GL, Williams JI, et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single center, prospective, randomized, double masked, placebo controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther. 2009;31:1908-1921.
11. Williams JI, Schooley GL, Gow JA, McNamara TR. Bepreve 1.5% provides clinically meaningful reduction in allergen-induced ocular itching for subjects in an analysis of two phase 3 conjunctival allergen challenge (CAC) clinical trials. [AAAI abstract 151]. J Allergy Clin Immunol. 2010;125(2 Suppl 1):AB38.
12. Clark JC, Williams JI, Gow JA, et al. Bepotastine besilate ophthalmic solution 1.5% rapidly eliminates ocular itching in more severely allergic subjects in the conjunctival allergen challenge model of allergic conjunctivitis. Poster presented at the Eastern Allergy Conference, Palm Beach, FL, May 6-9, 2010.
13. Pataday™. [Package insert]. Fort Worth, TX: Laboratories Inc; 2010.
14. Berdy GJ, Spangler DL, Bensch G, et al. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther. 2000;22:826-833.
15. Abelson MB, Greiner JV. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Curr Med Res Opin. 2004;20:1953-1958.
16. Hashiguchi K, Tang H, Fujita T, Suematsu K, Gotoh M, Okubo K. Bepotastine besilate tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO Chamber). Expert Opin Pharmacother. 2009;10:523-529.
17. Patanase® Nasal Spray [Prescribing information]. Fort Worth, TX: Alcon Laboratories Inc; 2008.
18. Spears K, McKee E, Edmonson W. Anti-allergy drop comfort and cost. Optometry. 2011;82:386.
19. Artal MN, Luna JD, Discepola M. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Acta Ophthalmol Scand Suppl. 2000;230:64-65.
20. Epstein AB, van Hoven PT, Kaufman A, Carr WW. Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clin Ophthalmol. 2009;3:329-336.
21. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;38: S2-S6.